Ewing's sarcoma

The Washington, D.C. Auto Show and Washington Area Hyundai Dealers Team up to Support Georgetown Lombardi and Children’s National Hospital Through “Hyundai Hands On Hope” Contest

Retrieved on: 
Wednesday, January 18, 2023
National Cancer Institute, American Cancer Society, Nursing, Hyundai Motor America, Washington Auto Show, MD, Ewing's sarcoma, Partnership, Healthcare in Washington, D.C., Contest, Cancer, Hope, Hyundai, Georgetown, MedStar Health, U.S. News & World Report, Walter E. Washington Convention Center, Georgetown University Medical Center, Degenerative disease, Research, Human, Washington Convention Center, Walter, Hackensack Meridian Health, News, Clinical trial, Georgetown Lombardi Comprehensive Cancer Center, Children's National Hospital, NCI, NCI-designated Cancer Center, Child, Hospital, Diagnosis, Harwell Science and Innovation Campus, L Street Bridge, Health, Motor vehicle, Medicine, Birth control, Machine tool, Wheel, D.C, NW

Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”

Key Points: 
  • Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”
    Six contestants will compete for a brand-new 2023 Hyundai IONIQ5 over the 44-hour contest period.
  • For Georgetown Lombardi, its grant will be put towards funding pediatric cancer research.
  • "Every 36 minutes a child is diagnosed with pediatric cancer,” shared Kevin Reilly, President of The Washington Area Hyundai Dealers.
  • A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington, D.C., area.

Stopping a rare childhood cancer in its tracks

Retrieved on: 
Thursday, January 19, 2023
Drug development, ETV6, Cold Spring Harbor Laboratory, Cell, Neoplasm, Behavior, Cold, Growth, Patient, CSHL, SPRING, Sarcoma, Research, Cancer, Ewing's sarcoma, Dietary supplement, Vaccine, Christopher Vakoc

Their experiments show that the cells causing this cancer can essentially be reprogrammed with the flick of a genetic switch.

Key Points: 
  • Their experiments show that the cells causing this cancer can essentially be reprogrammed with the flick of a genetic switch.
  • Shutting down a single protein forces the cancer cells to take on a new identity and behave like normal connective tissue cells, a dramatic change that reins in their growth.
  • This discovery suggests researchers may be able to stop Ewing sarcoma by developing a drug that blocks the protein known as ETV6.
  • They say their biochemical analyses, which identify specific spots in the ETV6 protein that are key to its function in cancer cells, could help guide drug development.

Global Bone Cancer Diagnosis and Therapeutics Market Report 2022: R&D and Technological Advancements & New Product Launches to Bolster Growth - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Biotechnology, Health, Oncology, Medical Devices, News, Paget's disease, Bayer, Novartis, R, Therapy, Multiple myeloma, Diagnosis, Health, Ewing's sarcoma, Amgen, Denosumab, Growth, Patient, Transplant, Cancer, BeiGene, Pfizer, Merck & Co., Bone metastasis, Chondrosarcoma, Acquisition, Bone, Medical device, Agriculture, Pharmaceutical industry, Medical imaging, Marketing, Osteosarcoma

The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • However, lack of awareness in under developed nations with regards to diagnosis and therapeutics along with high cost involvement in treatment are some major factors constraints that are hindering the growth of the global bone cancer diagnosis and therapeutics market.
  • New product launches in the market are likely to drive the growth of the global bone cancer diagnosis and therapeutics market.
  • Key players of the global bone cancer diagnosis and therapeutics market are Amgen Inc., Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others.

Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Life, CMML, Cancer prevention, Azacitidine, Sarcoma, Clinical trial, Annual report, Effectiveness, Hematological Cancer Research Investment and Education Act, Salinicola salarius, Cancer Prevention and Research Institute of Texas, Food, MDS, FDA, Poster, Safety, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, MD Anderson Cancer Center, SUSAR, Ewing's sarcoma, Drug development, Survival, Research, Society, Research institute, LSD1, Index (publishing), Biology, University, Patient, Pharmaceutical industry, IND

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that investigators in the Department of Leukemia at the University of Texas MD Anderson Cancer Center presented clinical data on seclidemstat in patients with MDS and CMML at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition underway in New Orleans and virtually.

Key Points: 
  • of the Department of Leukemia and is available in the Investors Events and Presentations section of Salarius’ website here .
  • As of October 2022, nine patients were enrolled with a median follow-up time of 3.9 months.
  • Typically, overall survival is four to six months for patients after failing therapy with hypomethylating agents.
  • The Phase 1 dose-escalation portion of this study will evaluate up to six dose levels of seclidemstat.

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Life, Cancer prevention, Sarcoma, Clinical trial, Annual report, Effectiveness, Hematological Cancer Research Investment and Education Act, Cancer Prevention and Research Institute of Texas, Letter, Food, FDA, Poster, Safety, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, Lenalidomide, Deuterium, SUSAR, Drug discovery, Ewing's sarcoma, Drug development, Research, Society, NHL, Research institute, Biology, Patient, MD Anderson Cancer Center, Rituximab, Vaccine, Pharmaceutical industry, Salinicola salarius, IND, DLBCL

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that yesterday Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, presented positive SP-3164 preclinical data at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition underway in New Orleans and virtually.

Key Points: 
  • Avadomide is an extensively studied clinical compound that has demonstrated encouraging single-agent and combination-therapy efficacy in non-Hodgkin’s lymphomas (NHL) and other hematologic malignancies.
  • This, along with the data presented at ASH showing compelling SP-3164 activity in lymphoma models, supports SP-3164’s potential in NHL for the clinical trial planned for 2023.
  • Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.
  • Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

Retrieved on: 
Thursday, December 8, 2022
Conference, Cancer prevention, Sarcoma, Hematological Cancer Research Investment and Education Act, Salinicola salarius, Cancer Prevention and Research Institute of Texas, PIN, Food, Webcast, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, International, MD Anderson Cancer Center, Ewing's sarcoma, Society, Research institute, Biology, Lymphatic system, Patient, Pharmaceutical industry

New preclinical data with Salarius’ targeted protein degrader SP-3164 being presented at ASH will also be reviewed, along with previously announced SP-3164 preclinical data that was presented at the 5th Annual Targeted Protein Degradation Conference.

Key Points: 
  • New preclinical data with Salarius’ targeted protein degrader SP-3164 being presented at ASH will also be reviewed, along with previously announced SP-3164 preclinical data that was presented at the 5th Annual Targeted Protein Degradation Conference.
  • Salarius encourages participants to pre-register for the conference call here to receive a dedicated dial-in number and PIN.
  • Participants may register at any time, including up to and after the call start time.
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options.

St. Jude Children’s Research Hospital Celebrates 60th Anniversary and 19 Years of the St. Jude Thanks and Giving Campaign With a Week of Stories On NBC’s TODAY Show

Retrieved on: 
Thursday, November 17, 2022
TV and Radio, Managed Care, Foundation, Philanthropy, Hospitals, Science, Family, Consumer, Entertainment, Health, Other Philanthropy, Research, Teens, Parenting, Children, Baby, Maternity, Oncology, Father, Ewing's sarcoma, Friends, Food, The Plaza, Cancer, Insurance, Love, National Cancer Registrars Association, Life, Housing, Survivor, Town square, NCI-designated Cancer Center, Child, Craniopharyngioma, Travel, Hospital, National Cancer Institute, Hope, The Holocaust and the United Nations Outreach Programme, Survival rate, Patient, Fashion, Jude the Apostle

We are so grateful to our St. Jude Thanks and Giving partners and friends at TODAY for helping highlight our patients journeys and showing the difference that every person can make when they give to St. Jude.

Key Points: 
  • We are so grateful to our St. Jude Thanks and Giving partners and friends at TODAY for helping highlight our patients journeys and showing the difference that every person can make when they give to St. Jude.
  • St. Jude Childrens Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Exhibition, Review, Private Securities Litigation Reform Act, Hematological Cancer Research Investment and Education Act, Azacitidine, Ministry of Education (Malaysia), MD Anderson Cancer Center, Food, Nasdaq, Sarcoma, Research, Myelodysplastic syndrome, Biology, Society, Lymphatic system, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Research institute, SEC, Annual report, SUSAR, U.S. Securities and Exchange Commission, Food and Drug Administration, Drug development, Clinical trial, University, Patient, CEO, Drug discovery, Acquisition, Chronic myelomonocytic leukemia, Ewing's sarcoma, ASH, Monroe Dunaway Anderson, FDA, Investor, Trial of the century, Cryptocurrency, Pharmaceutical industry, Aquaculture, IND, Salinicola salarius

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.

Key Points: 
  • HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.
  • The increase in net loss was due to higher operating expenses, including development spending on SP-3164, which was acquired in January 2022.
  • As of September 30, 2022, Salarius had cash, cash equivalents and restricted cash of $16.8 million, compared with $29.2 million as of December 31, 2021.
  • Salarius Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options.

Intermountain Healthcare and Las Vegas Raiders Honor Cancer Patients and Survivors During Ceremony with Musician Rachel Platten

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Hospital, Chase Garbers, Raider, Health, Survivor, American Childhood Cancer Organization, Ewing's sarcoma, Las Vegas Raiders, Bone, Neoplasm, Emma, Family, Volleyball, Monti, Diagnosis, Frazier Healthcare Partners, Cancer, Zárate, Brain, Time, Intermountain Healthcare, Friends, A. J. Cole, Patient, Breast cancer, Physician, Lymphoma, Ageing, St. George Regional Hospital, Hodgkin lymphoma, Football, Allegiant Stadium, Pharmaceutical industry, Medical imaging, Vaccine, Oligodendroglioma, Intermountain

Las Vegas, NV, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intermountain Healthcare and the Las Vegas Raiders honored five cancer survivors last month during the pregame show against Houston at Allegiant Stadium.

Key Points: 
  • Las Vegas, NV, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intermountain Healthcare and the Las Vegas Raiders honored five cancer survivors last month during the pregame show against Houston at Allegiant Stadium.
  • During that pregame performance, five Intermountain Healthcare cancer survivors were recognized in front of an Allegiant Stadium audience of nearly 61,000 fans for their courageous fight.
  • Intermountain Healthcare is the Official Healthcare Partner of the Raiders and a Founding Partner of Allegiant Stadium.
  • Audrey Monti, a Las Vegas mother of two, was an avid runner and indoor cyclist before her breast cancer diagnosis.

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Patient, Lymphoid neoplasms with plasmablastic differentiation, Private Securities Litigation Reform Act, Society, Biology, Lymphoma, FDA, IKZF1, University, Annual report, U.S. Securities and Exchange Commission, Clinical trial, MD Anderson Cancer Center, Ewing's sarcoma, Research institute, SEC, Department, 2021 Essex County Council election, Food, GLOBE, ASH, SUSAR, CMML, Lenalidomide, Cancer, Drug development, Myelodysplastic syndrome, Sarcoma, Salinicola salarius, Efficiency, MDS, Research, Drug resistance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Review, Pharmacology, Life, LSD1, Exposition, Food and Drug Administration, Investor, Chronic myelomonocytic leukemia, Effectiveness, Trial of the century, Hematological Cancer Research Investment and Education Act, NASDAQ, MD, Pharmaceutical industry, Vaccine, IND, Azacitidine

One abstract highlights preclinical work by Salarius with SP-3164 and the other highlights clinical work by collaborators at the University of Texas MD Anderson Cancer Center with seclidemstat.

Key Points: 
  • One abstract highlights preclinical work by Salarius with SP-3164 and the other highlights clinical work by collaborators at the University of Texas MD Anderson Cancer Center with seclidemstat.
  • SP-3164 showed increased IKZF1 degradation efficiency compared with other molecular glues and significant anti-cancer activity as a monotherapy in an in vivo lymphoma mouse xenograft model.
  • Salarius Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options.
  • This announcement and the referenced presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.